Dissecting the Thrombotic Events in the Presence of Antiphospholipid Antibodies in COVID-19 Spanish Patients
Several thrombotic complications in patients affected with SARS-CoV-2 have been reported.
Single-centre pilot study aimed to analyse the coexistence of antiphospholipid antibodies and thrombotic events on SARS-CoV-2 infected patients.
Antiphospholipid antibodies were measured by solid phase enzyme immunoassay. Clinical data were collected from electronic history and clinical records.
Over 25 patients studied we report four cases of COVID-19 patients who presented circulating antiphospholipid antibodies and arterial or venous thrombotic events. No patient had a previous history of thrombosis. Two cases presented with pulmonary embolism, one with pulmonary embolism and pulmonary infarction and one with a stroke. All of them showed positive anti-cardiolipin antibodies. One patient died and three were discharged.
The presence of antiphospholipid antibodies in these patients might represent an epiphenomenon secondary to the immune stimulation by the virus. It could be reasonable to consider measuring antiphospholipid antibodies as part of the study of a thrombotic event in COVID-19 patients to better understand the impact of these antibodies in the development of thrombotic events and we highlight the value of a periodic determination to define the need of long-term anticoagulant therapy.
1.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
2. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol 2020;15:359–86.
3. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.
4. Gomez-Arbelaez D, Ibarra-Sanchez G, Garcia-Gutierrez A, Comanges-Yeboles A, Ansuategui-Vicente M, Gonzalez-Fajardo JA. COVID-19-Related Aortic Thrombosis: A Report of Four Cases. Ann Vasc Surg 2020;67:10–3.
5. Shams A, Ata F, Mushtaq K, Munir W, Yousaf Z. Coronary thrombosis in a young male with COVID-19. IDCases 2020;21:e00923.
6. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194:101–15.
7. Rodziewicz M, D'Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis 2020;12:1759720X20910855.
8. Cervera R, Asherson RA, Acevedo ML, Gómez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004;63:1312–7.
9. Plummer MP, Young AMH, O'Leary R, Damian MS, Lavinio A. Probable Catastrophic Antiphospholipid Syndrome with intracerebral hemorrhage secondary to Epstein-Barr Viral infection. Neurocrit Care 2018;28:127–32.
10. Martirosyan A, Aminov R, Manukyan G. Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation. Front Immunol 2019;10:1609.
11. Cavalli E, Bramanti A, Ciurleo R, Tchorbanov AI, Giordano A, Fagone P, et al. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). Int J Mol Med 2020;46:903–12.
12. Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, MartinToutain I, Mathian A, et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability? J Intern Med 2021;289:422–4.
13. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e38.
14. Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation? J Thromb Haemost 2020;18:2191–201.
15. Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the Anti-Phospholipid Syndrome. Front Immunol 2020;11:584241.
16. Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, Del Toro-Cervera J, di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 2020;192:113–5.
17. Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020;12:eabd3876.
18. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089–98.
19. Garcia-Carrasco M, Mendoza-Pinto C, Macias-Diaz S, Vazquez de Lara F, Etchegaray-Morales I, Galvez-Romero JL, et al. The role of infectious diseases in the catastrophic antiphospholipid syndrome. Autoimmun Rev 2015;14:1066–71.
20. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmun Rev 2006;6:64–7.
21. Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, Meroni PL. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008;17:937–42.
22. Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, et al. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One 2011;6:e23800.
23. Cronin SJF, Woolf CJ, Weiss G, Penninger JM. The Role of Iron Regulation in Immunometabolism and Immune-Related Disease. Front Mol Biosci 2019;6:116.
24. Agmon-Levin N, Rosário C, Katz BS, Zandman-Goddard G, Meroni P, Cervera R, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 2013;22:1327–35.
25. Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, et al. The looming storm: Blood and cytokines in COVID-19. Blood Rev 2021;46:100743.
26. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014;13:699–707.
27. Domenico Sebastiani G, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2003;2:387–94.